Therapieentscheidung bei Patienten mit operablem, nicht metastasiertem Ösophaguskarzinom

Zusammenfassung

Hintergrund: Die Therapie des Ösophaguskarzinoms wird kontrovers diskutiert. Gegenstand dieser Arbeit sind die Therapieoptionen beim operablen, nicht metastasierten Ösophaguskarzinom.
Material und Methoden: Aktuelle Literaturrecherche über die verschiedenen Behandlungsoptionen beim klassischen Ösophaguskarzinom.
Ergebnisse: Das Ösophaguskarzinom wird nach multiplen Kriterien therapiert. Die Ösophagektomie im multimodalen Setting hat das beste Outcome. Die definitive Radiochemotherapie als konservatives Regime bietet Risikopatienten eine Therapiealternative.
Schlussfolgerung: Die Therapieentscheidung bei Patienten mit operablem, nicht metastasiertem Ösophaguskarzinom muss anhand eines standardisierten Stagings und nach Abklärung aller Risikofaktoren erfolgen.

Abstract

Background: Therapy for oesophageal carcinoma is a subject of controversial debate. The aim of this study is to answer the question how the therapeutic decision in patients with operable, non-metastatic oesophageal cancer should be made.
Materials and Methods: A systematic literature research regarding different therapeutic strategies in patients with oesophageal cancer was undertaken.
Results: Multiple criteria influence the therapy for oesophageal carcinoma. Radical oesophagectomy in a multimodal setting is the therapy of choice. Definitive chemoradiation is a conservative option for high risk patients.
Conclusion: Therapeutic decisions in patients with oesophageal cancer should only be made after standardised staging and accurate risk analysis.

Schlüsselwörter

Ösophaguskarzinom - Ösophagektomie - definitive Radiochemotherapie

Key words

oesophageal cancer - oesophagectomy - definitive chemoradiation

• Literatur

• 1 Pech O, Manner H, Ell C et al. Reply to letter: „For patients with early esophageal cancer endoscopic mucosa resection is not the end of the story!“. Ann Surg 2013; 257: e22-e23
• 2 Metzger R, Lorenz D, Gockel I et al. pT2 Adenocarcinoma of the esophagus: early or advanced cancer?. Ann Thorac Surg 2013; 96: 1840-1845
• 3 Lordick F, Hölscher AH, Haustermans K et al. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013; 398: 177-187
• 4 Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol 2007; 4: 282-294
• 5 Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174
• 6 Ohtsu A, Boku N, Muro K et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-2921
• 7 Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598
• 8 Gwynne S, Falk S, Gollins S et al. Oesophageal Chemoradiotherapy in the UK-current practice and future directions. Clin Oncol (R Coll Radiol) 2013; 25: 368-377
• 9 Crosby T, Hurt CN, Falk S et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013; 14: 627-637
• 10 Smit JK, Muijs CT, Burgerhof JG et al. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. Ann Surg Oncol 2013; 20: 1985-1992
• 11 Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317
• 12 Bedenne L, Michel P, Bouché O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168
• 13 Kato H, Sato A, Fukuda H et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 2009; 39: 638-643
• 14 van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
• 15 Bollschweiler E, Metzger R, Drebber U et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20: 231-238
• 16 Schröder W, Bollschweiler E, Kossow C et al. Preoperative risk analysis – a reliable predictor of postoperative outcome after transthoracic esophagectomy?. Langenbecks Arch Surg 2006; 391: 455-460
• 17 Pech O, Bollschweiler E, Manner H et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrettʼs esophagus at two high-volume centers. Ann Surg 2011; 254: 67-72
• 18 Vallböhmer D, Schröder W, Brabender J et al. [Oesophageal cancer: current status of multimodality therapy]. Zentralbl Chir 2011; 136: 312-316
• 19 Hölscher AH, Fetzner UK. Modern diagnostics and stage-oriented surgery: therapy of adenocarcinoma of the esophagogastric junction. Chirurg 2012; 83: 702-708 710–711
• 20 Hulscher JB, van Sandick JW, de Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347 (21) 1662-1669
• 21 Omloo JM, Lagarde SM, Hulscher JB et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000
• 22 Kutup A, Izbicki JR, Bollschweiler E et al. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic or transhiatal esophagectomy?. Ann Surg 2013; [in press]
• 23 Stein HJ, Feith M, Mueller J et al. Limited resection for early adenocarcinoma in Barrettʼs esophagus. Ann Surg 2000; 232: 733-742
• 24 Gutschow CA, Schröder W, Wolfgarten E et al. [Merendino procedure with preservation of the vagus for early carcinoma of the gastroesophageal junction]. Zentralbl Chir 2004; 129: 276-281
• 25 Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
• 26 Arnott SJ, Duncan W, Gignoux M et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; (4) CD001799
• 27 Hölscher AH, Bollschweiler E. Choosing the best treatment for esophageal cancer: criteria for selecting the best multimodal therapy. Recent Results Cancer Res 2012; 196: 169-177
• 28 Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856
• 29 Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2003; (4) CD001556
• 30 Greer SE, Goodney PP, Sutton JE et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005; 137: 172-177
• 31 Abou-Jawde RM, Mekhail T, Adelstein DJ et al. Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest 2005; 128: 250-255
• 32 Bollschweiler E, Metzger R, Drebber U et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20: 231-238
• 33 Ott K, Weber WA, Lordick F et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-4698
• 34 Vallböhmer D, Hölscher AH, Dietlein M et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009; 250: 888-894
• 35 Metzger R, Warnecke-Eberz U, Alakus H et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg 2012; 16: 26-34
• 36 Lordick F, Ebert M, Stein HJ. Current treatment approach to locally advanced esophageal cancer: is resection mandatory?. Future Oncol 2006; 2: 717-721
• 37 Teoh AY, Chiu PW, Yeung WK et al. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 2013; 24: 165-171
• 38 Piessen G, Messager M, Mirabel X et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg 2013; 258: 793-799
• 39 Tougeron D, Scotté M, Hamidou H et al. Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?. J Surg Oncol 2012; 105: 761-766
• 40 Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer–a meta-analysis of the randomized trials. Cancer Treat Rev 2012; 38: 599-604
• 41 Motoori M, Yano M, Ishihara R et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1 bN0M0 esophageal cancer. Ann Surg Oncol 2012; 19: 2135-2141
• 42 Krüger-Brand HE. Patientenrechte: Patienten werden selbstbewusster. Dtsch Arztebl 2013; 110: A-548/B-488/C-488
• 43 Gutschow CA, Hölscher AH, Leers J et al. Health-related quality of life after Ivor Lewis esophagectomy. Langenbecks Arch Surg 2013; 398: 231-237
• 44 Stacey D, Bennett CL, Barry MJ et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011; (10) CD001431
• 45 Melis M, Weber J, Shridhar R et al. Body mass index and perioperative complications after oesophagectomy for adenocarcinoma: a systematic database review. BMJ Open 2013; 3: 3
• 46 McLoughlin JM, Lewis JM, Meredith KL. The impact of age on morbidity and mortality following esophagectomy for esophageal cancer. Cancer Control 2013; 20: 144-150
• 47 Miyata H, Yamasaki M, Takahashi T et al. Larynx-preserving limited resection and free jejunal graft for carcinoma of the cervical esophagus. World J Surg 2013; 37: 551-557
• 48 Shen KR, Harrison-Phipps KM, Cassivi SD et al. Esophagectomy after anti-reflux surgery. J Thorac Cardiovasc Surg 2010; 139: 969-975
• 49 Gockel I, Lang H, Mildenberger P. Necessity of preoperative imaging of the gastro-epiploic arcade prior to esophageal resection. Hepatogastroenterology 2009; 56: 711-713